Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant Advanced Non-small Cell Lung Cancer
With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without dr...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Chinês |
| منشور في: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021-10-01
|
| سلاسل: | Chinese Journal of Lung Cancer |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|